Travere Therapeutics Surges 33% After FDA Approves the Only Drug for Rare Kidney Disease
NEW YORK, April 15 —
Travere Therapeutics jumped 33-44% after the FDA granted full approval to FILSPARI, the first drug ever approved for FSGS.
- TVTX shares surged to around $42.13, approaching 20-year highs, after the FDA cleared FILSPARI (sparsentan) for focal segmental glomerulosclerosis
- The stock trades at 10.1x forward earnings on $491mn in TTM revenue, cheap for a company that just became the sole approved therapy in a rare disease
- Guggenheim maintained coverage and raised its price target to $54.00, implying roughly 28% upside from current levels
What Actually Happened
The FDA converted FILSPARI's accelerated approval into a full approval for FSGS, a rare kidney scarring disease that progressively destroys the organ's filtering ability. That distinction matters more than it sounds. Accelerated approvals carry confirmatory trial requirements, the threat of withdrawal, and payer reluctance to cover. Full approval eliminates all three. FILSPARI is now the only FDA-approved therapy for FSGS. Not the best option. The only one. Every nephrologist treating FSGS patients previously had zero approved drugs to prescribe. Now there is exactly one, and Travere owns it.
The Catch
FSGS is rare. Estimates put the U.S. patient population in the tens of thousands, which caps the addressable market. Travere is already generating $491mn in TTM revenue. The question is how much new volume a full approval label unlocks beyond what physicians were already prescribing under accelerated approval. Plenty of doctors were already writing scripts. The bull case depends on a wave of new patient starts from physicians who refused to prescribe until full approval came through. That cohort may be smaller than the stock move suggests. A 33-44% single-day surge bakes in heavy optimism for a drug that was already on the market.
Bottom Line
This is a genuine de-risking event. The regulatory overhang is gone, the competitive moat is real — no approved competitors exist — and 10.1x forward earnings looks reasonable for a rare disease monopoly. But the easy money was made the day of the move. From here, the stock needs proof that full approval drives accelerating prescription volumes, not just a label upgrade on existing sales. The tell is FILSPARI quarterly revenue in the next earnings report. That number will show whether the market priced this correctly or sprinted ahead of the fundamentals.
Travere Therapeutics doesn't have a Basis Report yet. Generate one here to see the full financial picture.
Basis Report does not hold positions in securities discussed. This is not investment advice.